BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,769,000 | -35.9% | 23,350 | -25.5% | 0.03% | -22.5% |
| Q4 2021 | $4,318,000 | -93.4% | 31,336 | -93.4% | 0.04% | -93.7% |
| Q3 2021 | $65,771,000 | +23.7% | 473,478 | -13.6% | 0.63% | +33.8% |
| Q2 2021 | $53,178,000 | +33.4% | 547,777 | -6.1% | 0.47% | +28.1% |
| Q1 2021 | $39,873,000 | -29.2% | 583,367 | -11.3% | 0.37% | -29.1% |
| Q4 2020 | $56,344,000 | +17.6% | 657,380 | -10.8% | 0.52% | -0.9% |
| Q3 2020 | $47,912,000 | -38.9% | 736,989 | -31.2% | 0.53% | -44.9% |
| Q2 2020 | $78,364,000 | +117.3% | 1,071,866 | +1.1% | 0.96% | +57.5% |
| Q1 2020 | $36,068,000 | -41.9% | 1,059,893 | -7.0% | 0.61% | -29.7% |
| Q4 2019 | $62,067,000 | +30.4% | 1,140,101 | -0.1% | 0.86% | +20.4% |
| Q3 2019 | $47,613,000 | +1796.9% | 1,141,243 | +1891.3% | 0.72% | +309.7% |
| Q2 2019 | $2,510,000 | – | 57,312 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |